Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986393 + CC-92480 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986393 | CC-95266|CC 95266|CC95266|BMS 986393|BMS986393 | BMS-986393 (CC-95266) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting GPRC5D, which potentially results in antitumor activity (Blood (2022) 140 (Supplement 1): 883-885). | ||
CC-92480 | CELMoD CC92480|CC 92480|Mezigdomide|BMS-986348|BMS986348|BMS 986348 | CC-92480 binds to and modulates activity of the ubiquitin E3 ligase complex member Cereblon (CRBN), which may induce ubiquitination and degradation of transcription factors in T-lymphocytes, resulting in immune system activation (Blood (2019) 134 (Supplement_1): 1812, PMID: 32130004). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06121843 | Phase I | BMS-986393 + Iberdomide BMS-986393 + CC-92480 BMS-986393 + CC-93269 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |